AARTI DRUGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 503.8 INR | +0.67% |
|
+1.51% | +3.01% |
| Mar. 29 | Aarti Drugs Limited Announces Executive Cessation | CI |
| Jan. 31 | Aarti Drugs Begins Manufacturing Dermatology Products in Tarapur, India Facility | MT |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 15,103 | 11,785 | 64,755 | 39,725 | 31,280 | 46,312 | - | - |
| Enterprise Value (EV) 1 | 15,103 | 11,785 | 64,755 | 39,725 | 31,280 | 46,312 | 46,312 | 46,312 |
| P/E ratio | 16.6 x | 8.35 x | 23.1 x | 19.4 x | 18.8 x | 26.9 x | 18.5 x | 14.7 x |
| Yield | 0.16% | 0.4% | 0.36% | 0.23% | - | 0.93% | 1.35% | 1.69% |
| Capitalization / Revenue | 0.97 x | 0.65 x | 3.01 x | 1.6 x | 1.15 x | 1.77 x | 1.57 x | 1.39 x |
| EV / Revenue | 0.97 x | 0.65 x | 3.01 x | 1.6 x | 1.15 x | 1.77 x | 1.57 x | 1.39 x |
| EV / EBITDA | 7.28 x | 4.5 x | 14.8 x | 12.1 x | 10.2 x | 14.5 x | 10.8 x | 8.95 x |
| EV / FCF | 21.9 x | 5.81 x | 97.1 x | -53.7 x | -103 x | 129 x | 44.4 x | 30 x |
| FCF Yield | 4.56% | 17.2% | 1.03% | -1.86% | -0.97% | 0.78% | 2.25% | 3.34% |
| Price to Book | 2.75 x | 1.81 x | 7.09 x | 3.83 x | 2.62 x | 3.53 x | 3.09 x | 2.67 x |
| Nbr of stocks (in thousands) | 94,328 | 93,200 | 93,200 | 92,600 | 92,600 | 91,935 | - | - |
| Reference price 2 | 160.1 | 126.4 | 694.8 | 429.0 | 337.8 | 503.8 | 503.8 | 503.8 |
| Announcement Date | 5/15/19 | 5/15/20 | 5/15/21 | 5/9/22 | 4/29/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 15,609 | 18,061 | 21,548 | 24,886 | 27,160 | 26,118 | 29,484 | 33,388 |
| EBITDA 1 | 2,074 | 2,618 | 4,371 | 3,294 | 3,056 | 3,186 | 4,275 | 5,175 |
| EBIT 1 | 1,648 | - | 3,872 | 2,794 | 2,553 | 2,583 | 3,612 | 4,472 |
| Operating Margin | 10.56% | - | 17.97% | 11.23% | 9.4% | 9.89% | 12.25% | 13.39% |
| Earnings before Tax (EBT) 1 | 1,310 | 1,853 | 3,690 | 2,700 | 2,242 | 2,306 | 3,353 | 4,218 |
| Net income 1 | 897.5 | 1,414 | 2,804 | 2,050 | 1,663 | 1,730 | 2,515 | 3,163 |
| Net margin | 5.75% | 7.83% | 13.01% | 8.24% | 6.12% | 6.62% | 8.53% | 9.47% |
| EPS 2 | 9.620 | 15.14 | 30.09 | 22.12 | 17.97 | 18.70 | 27.20 | 34.20 |
| Free Cash Flow 1 | 688.2 | 2,028 | 667.2 | -740.4 | -304.7 | 359 | 1,042 | 1,546 |
| FCF margin | 4.41% | 11.23% | 3.1% | -2.98% | -1.12% | 1.37% | 3.53% | 4.63% |
| FCF Conversion (EBITDA) | 33.19% | 77.44% | 15.26% | - | - | 11.27% | 24.37% | 29.87% |
| FCF Conversion (Net income) | 76.68% | 143.39% | 23.79% | - | - | 20.75% | 41.43% | 48.88% |
| Dividend per Share 2 | 0.2500 | 0.5000 | 2.500 | 1.000 | - | 4.700 | 6.800 | 8.500 |
| Announcement Date | 5/15/19 | 5/15/20 | 5/15/21 | 5/9/22 | 4/29/23 | - | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,302 | 5,018 | 5,800 | 5,796 | 6,348 | 6,943 | 6,220 | 6,877 | 6,640 | 7,424 | 6,611 |
| EBITDA | 1,058 | 809.3 | 796.9 | 737.4 | 900 | 860 | 671.3 | 742.7 | - | - | - |
| EBIT | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - |
| Net income | 680.3 | 516.5 | 488.1 | 425.8 | - | 553.4 | 347.9 | 387.5 | - | - | - |
| Net margin | 12.83% | 10.29% | 8.42% | 7.35% | - | 7.97% | 5.59% | 5.63% | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 1/25/21 | 5/15/21 | 7/27/21 | 10/27/21 | 1/31/22 | 5/9/22 | 7/27/22 | 10/20/22 | 1/27/23 | 4/29/23 | 7/21/23 |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 688 | 2,028 | 667 | -740 | -305 | 359 | 1,042 | 1,546 |
| ROE (net income / shareholders' equity) | 18% | 23.1% | 35.8% | 21% | 14.9% | 13.8% | 17.8% | 19.4% |
| ROA (Net income/ Total Assets) | 6.29% | 9.1% | - | 10.3% | - | - | - | - |
| Assets 1 | 14,261 | 15,535 | - | 19,870 | - | - | - | - |
| Book Value Per Share 2 | 58.30 | 69.90 | 98.00 | 112.0 | 129.0 | 143.0 | 163.0 | 189.0 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 743 | 480 | 881 | 1,437 | 1,647 | 3,000 | 1,500 | 1,000 |
| Capex / Sales | 4.76% | 2.66% | 4.09% | 5.77% | 6.06% | 11.49% | 5.09% | 3% |
| Announcement Date | 5/15/19 | 5/15/20 | 5/15/21 | 5/9/22 | 4/29/23 | - | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
503.8
INR
Average target price
562
INR
Spread / Average Target
+11.56%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +3.01% | 555M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- AARTIDRUGS Stock
- Financials Aarti Drugs Limited
